Dr Angie Lackenby has worked in the National Influenza Centre (NIC) UK since 2005 and is currently responsible for the molecular section, delivering antiviral susceptibility and genetic characterisation of influenza viruses. She established influenza antiviral susceptibility surveillance in the NIC and has worked with the European Influenza Surveillance Network (EISN) to expand surveillance capability across Europe. Her work with EISN and Dr Olav Hungnes led to the identification in 2007/8 of oseltamivir resistant A(H1N1) virus in Norway. She is an active member of the WHO GISRS Antiviral Susceptibility Surveillance Working Group.

She maintains an active research portfolio on influenza antivirals and continues to expand antiviral susceptibility characterisation in the NIC, focussing on baloxavir genotypic and phenotypic assays. Her work with Imperial College London Respiratory Infections Health Protection Research Unit led to the first identification of influenza virus resistance to Favipiravir. She contributes to UK influenza antiviral treatment and prophylaxis guidance and provides advice to UK clinicians on testing for influenza antiviral resistance.

Angie has 20 years’ experience of molecular biology and virology of influenza viruses. Prior to joining the NIC Angie completed her PhD on the host range determinants of avian influenza, with Professor Wendy Barclay and Dr John McCauley.

Back to isirv-AVG Committee